Literature DB >> 31965894

Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome.

Na Young Lee1, Sang Jun Yoon1, Dae Hee Han1, Haripriya Gupta1, Gi Soo Youn1, Min Jea Shin1, Young Lim Ham2, Min Jung Kwak3, Byung Yong Kim3, Jeong Seok Yu4,5, Do Yup Lee5, Tae-Sik Park6, Si-Hyun Park6, Byoung Kook Kim7, Hyun Chae Joung7, In Suk Choi7, Ji Taek Hong1,8, Dong Joon Kim1,8, Sang Hak Han9, Ki Tae Suk1,8.   

Abstract

Targeting the gut-liver axis by modulating the gut-microbiome can be a promising therapeutic approach in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of single species and a combination of Lactobacillus and Pediococcus in NAFLD mice model. Six-week male C57BL/6J mice were divided into 9 groups (n = 10/group; normal, Western diet, and 7 Western diet-strains [109 CFU/g, 8 weeks]). The strains used were L. bulgaricus, L. casei, L. helveticus, P. pentosaceus KID7, and three combinations (1: L. casei+L. helveticus, 2: L. casei+L. helveticus+P. pentosaceus KID7, and 3: L. casei+L. helveticus+L. bulgaricus). Liver/Body weight ratio, serum and stool analysis, liver pathology, and metagenomics by 16S rRNA-sequencing were examined. In the liver/body ratio, L. bulgaricus (5.1 ± 0.5), L. helveticus (5.2 ± 0.4), P. pentosaceus KID7 (5.5 ± 0.5), and combination1 and 2 (4.2 ± 0.6 and 4.8 ± 0.7) showed significant reductions compared with Western (6.2 ± 0.6)(p < 0.001). In terms of cholesterol and steatosis/inflammation/NAFLD activity, all groups except for L. casei were associated with an improvement (p < .05). The elevated level of tumor necrosis factor-α/interleukin-1β (pg/ml) in Western (65.8 ± 7.9/163.8 ± 12.2) was found to be significantly reduced in L. bulgaricus (24.2 ± 1.0/58.9 ± 15.3), L. casei (35.6 ± 2.1/62.9 ± 6.0), L. helveticus (43.4 ± 3.2/53.6 ± 7.5), and P. pentosaceus KID7 (22.9 ± 3.4/59.7 ± 12.2)(p < 0.01). Cytokines were improved in the combination groups. In metagenomics, each strains revealed a different composition and elevated Firmicutes/Bacteroidetes ratio in the western (47.1) was decreased in L. bulgaricus (14.5), L. helveticus (3.0), and P. pentosaceus KID7 (13.3). L. bulgaricus, L. casei, L. helveticus, and P. pentosaceus KID7 supplementation can improve NAFLD-progression by modulating gut-microbiome and inflammatory pathway.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; gut liver axis; liver function; microbiome; strains

Year:  2020        PMID: 31965894      PMCID: PMC7524267          DOI: 10.1080/19490976.2020.1712984

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  53 in total

1.  Probiotics for the hemodynamic alterations of patients with liver cirrhosis.

Authors:  A De Santis; G Famularo; C De Simone
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Search and clustering orders of magnitude faster than BLAST.

Authors:  Robert C Edgar
Journal:  Bioinformatics       Date:  2010-08-12       Impact factor: 6.937

3.  Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.

Authors:  Cyrielle Caussy; Meera Soni; Jeffrey Cui; Ricki Bettencourt; Nicholas Schork; Chi-Hua Chen; Mahdi Al Ikhwan; Shirin Bassirian; Sandra Cepin; Monica P Gonzalez; Michel Mendler; Yuko Kono; Irine Vodkin; Kristin Mekeel; Jeffrey Haldorson; Alan Hemming; Barbara Andrews; Joanie Salotti; Lisa Richards; David A Brenner; Claude B Sirlin; Rohit Loomba
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

Review 4.  Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.

Authors:  Min Seok Cho; Sang Yeol Kim; Ki Tae Suk; Byung-Yong Kim
Journal:  J Microbiol       Date:  2018-10-25       Impact factor: 3.422

Review 5.  Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.

Authors:  F Lirussi; E Mastropasqua; S Orando; R Orlando
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.

Authors:  A N Mavrogiannaki; I N Migdalis
Journal:  Int J Endocrinol       Date:  2013-04-03       Impact factor: 3.257

7.  Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study.

Authors:  Lisa Lindheim; Mina Bashir; Julia Münzker; Christian Trummer; Verena Zachhuber; Bettina Leber; Angela Horvath; Thomas R Pieber; Gregor Gorkiewicz; Vanessa Stadlbauer; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

8.  Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies.

Authors:  Seok-Hwan Yoon; Sung-Min Ha; Soonjae Kwon; Jeongmin Lim; Yeseul Kim; Hyungseok Seo; Jongsik Chun
Journal:  Int J Syst Evol Microbiol       Date:  2017-05-30       Impact factor: 2.747

9.  Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Hana Koutnikova; Bernd Genser; Milena Monteiro-Sepulveda; Jean-Michel Faurie; Salwa Rizkalla; Jürgen Schrezenmeir; Karine Clément
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

10.  Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients.

Authors:  Xiao Cui; Lei Ye; Jing Li; Ling Jin; Wenjie Wang; Shuangyue Li; Minghui Bao; Shouling Wu; Lifeng Li; Bin Geng; Xin Zhou; Jian Zhang; Jun Cai
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

View more
  20 in total

1.  Intestinal Microbiota Participates in the Protective Effect of HO-1/BMMSCs on Liver Transplantation With Steatotic Liver Grafts in Rats.

Authors:  Mengshu Yuan; Ling Lin; Huan Cao; Weiping Zheng; Longlong Wu; Huaiwen Zuo; Xiaorong Tian; Hongli Song
Journal:  Front Microbiol       Date:  2022-06-10       Impact factor: 6.064

2.  Lactococcus lactis KF140 Reduces Dietary Absorption of Nε - (Carboxymethyl)lysine in Rats and Humans via β-Galactosidase Activity.

Authors:  Ho-Young Park; Hye-Bin Lee; So-Young Lee; Mi-Jin Oh; Sang Keun Ha; Eunju Do; Hyun Hee L Lee; Jinyoung Hur; Kwang-Won Lee; Mi-Hyun Nam; Myoung Gyu Park; Yoonsook Kim
Journal:  Front Nutr       Date:  2022-06-24

Review 3.  Optimization of metabolomic data processing using NOREVA.

Authors:  Jianbo Fu; Ying Zhang; Yunxia Wang; Hongning Zhang; Jin Liu; Jing Tang; Qingxia Yang; Huaicheng Sun; Wenqi Qiu; Yinghui Ma; Zhaorong Li; Mingyue Zheng; Feng Zhu
Journal:  Nat Protoc       Date:  2021-12-24       Impact factor: 13.491

4.  Effect of Lactobacillus helveticus CD6 on serum lipid profile and indicators of liver function in high-fat diet fed Swiss albino mice.

Authors:  Mahesh P Patil; Jayesh J Ahire; Ulhas K Patil; Bharat Bhushan; Bhushan L Chaudhari
Journal:  3 Biotech       Date:  2021-05-15       Impact factor: 2.893

5.  NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data.

Authors:  Qingxia Yang; Yunxia Wang; Ying Zhang; Fengcheng Li; Weiqi Xia; Ying Zhou; Yunqing Qiu; Honglin Li; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

6.  Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis.

Authors:  Na Young Lee; Min Jea Shin; Gi Soo Youn; Sang Jun Yoon; Ye Rin Choi; Hyeong Seop Kim; Haripriya Gupta; Sang Hak Han; Byoung Kook Kim; Do Yup Lee; Tae Sik Park; Hotaik Sung; Byung Yong Kim; Ki Tae Suk
Journal:  Clin Mol Hepatol       Date:  2020-12-03

Review 7.  Pediococcus pentosaceus, a future additive or probiotic candidate.

Authors:  Shiman Jiang; Lingzhi Cai; Longxian Lv; Lanjuan Li
Journal:  Microb Cell Fact       Date:  2021-02-16       Impact factor: 5.328

8.  Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum.

Authors:  Na Young Lee; Hyun Chae Joung; Byoung Kook Kim; Byung Yong Kim; Tae Sik Park; Ki Tae Suk
Journal:  Gut Microbes       Date:  2020-11-09

Review 9.  Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.

Authors:  Leen J M Heyens; Dana Busschots; Ger H Koek; Geert Robaeys; Sven Francque
Journal:  Front Med (Lausanne)       Date:  2021-04-14

10.  Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease.

Authors:  Jeong Seok Yu; Gi Soo Youn; Jieun Choi; Chang-Ho Kim; Byung Yong Kim; Seung-Jo Yang; Je Hee Lee; Tae-Sik Park; Byoung Kook Kim; Yeon Bee Kim; Seong Woon Roh; Byeong Hyun Min; Hee Jin Park; Sang Jun Yoon; Na Young Lee; Ye Rin Choi; Hyeong Seob Kim; Haripriya Gupta; Hotaik Sung; Sang Hak Han; Ki Tae Suk; Do Yup Lee
Journal:  Clin Transl Med       Date:  2021-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.